Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients. The medication targets specific serotonin receptors to alleviate headache and associated symptoms rapidly.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality, regulatory compliance, and adherence to stringent standards to meet global healthcare needs.

Imigran (sumatriptan) is used within the Triptan class for the acute management of migraine. - Migraine with aura: provides rapid relief of headache and associated neurological symptoms. - Migraine without aura: reduces pain intensity and associated nausea or photophobia. - Acute episodic migraine: aborts attacks when taken at the first sign of a migraine episode.

Imigran may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or toes - Nausea or upset stomach - Dizziness or light‑headedness

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reaction (anaphylaxis)

When prescribing Imigran, several safety considerations should be evaluated. - Cardiovascular assessment: evaluate history of heart disease, ischemia, or uncontrolled hypertension. - Contraindicated in patients with known hypersensitivity to sumatriptan or other triptans. - Avoid use with ergot alkaloids or within 24 hours of another triptan dose. - Caution when combined with other serotonergic medications, such as SSRIs, SNRIs, or MAO inhibitors. - Monitor for signs of serotonin syndrome if patient is on serotonergic agents. - Store at below 25°C: keep in the original pack, protect from moisture.

Imigran can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Ergot alkaloids (e.g., ergotamine): combined use may cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Other triptans: concurrent use can lead to excessive vasoconstriction. - SSRIs, SNRIs, or other serotonergic agents: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance blood pressure effects. - Oral contraceptives: may slightly increase migraine frequency, monitor efficacy.